Abstract
We recently developed a computational tool (EczemaPred) for personalised prediction of AD severity dynamics using PO-SCORAD. We aim to investigate whether EczemaPred can be applied to predict POEM score recorded weekly. We used data from 247 AD patients aged 11 to 65 years in a dose-finding study with up to 6 measurements of POEM and daily symptom scores for POEM over 16 weeks. We investigated the influence of the recency bias in reporting POEM by computing the partial cross-correlation between the observed POEM score and daily symptom scores recorded on the previous seven days using linear mixed-effects models.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
